CN103561729B - 紫檀茋在制造用于治疗、缓解或预防焦虑的药物组合物中的应用 - Google Patents

紫檀茋在制造用于治疗、缓解或预防焦虑的药物组合物中的应用 Download PDF

Info

Publication number
CN103561729B
CN103561729B CN201280022178.5A CN201280022178A CN103561729B CN 103561729 B CN103561729 B CN 103561729B CN 201280022178 A CN201280022178 A CN 201280022178A CN 103561729 B CN103561729 B CN 103561729B
Authority
CN
China
Prior art keywords
pterostilbene
anxiolytic
doses
anxiety
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280022178.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN103561729A (zh
Inventor
阿格尼斯·M·里曼多
阿比尔·厄尔-阿勒菲
穆德·阿尔·拉希姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Mississippi
US Department of Agriculture USDA
Original Assignee
University of Mississippi
US Department of Agriculture USDA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Mississippi, US Department of Agriculture USDA filed Critical University of Mississippi
Publication of CN103561729A publication Critical patent/CN103561729A/zh
Application granted granted Critical
Publication of CN103561729B publication Critical patent/CN103561729B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280022178.5A 2011-05-11 2012-05-10 紫檀茋在制造用于治疗、缓解或预防焦虑的药物组合物中的应用 Expired - Fee Related CN103561729B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/105,470 2011-05-11
US13/105,470 US9439875B2 (en) 2011-05-11 2011-05-11 Anxiolytic effect of pterostilbene
PCT/US2012/037325 WO2012154956A2 (en) 2011-05-11 2012-05-10 Anxiolytic effect of pterostilbene

Publications (2)

Publication Number Publication Date
CN103561729A CN103561729A (zh) 2014-02-05
CN103561729B true CN103561729B (zh) 2016-03-09

Family

ID=47140003

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280022178.5A Expired - Fee Related CN103561729B (zh) 2011-05-11 2012-05-10 紫檀茋在制造用于治疗、缓解或预防焦虑的药物组合物中的应用

Country Status (9)

Country Link
US (1) US9439875B2 (enExample)
EP (1) EP2706992B1 (enExample)
JP (2) JP6027607B2 (enExample)
KR (1) KR101929074B1 (enExample)
CN (1) CN103561729B (enExample)
AU (1) AU2012253479B2 (enExample)
BR (1) BR112013028776B1 (enExample)
CA (1) CA2839309C (enExample)
WO (1) WO2012154956A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9439875B2 (en) * 2011-05-11 2016-09-13 The United States Of America, As Represented By The Secretary Of Agriculture Anxiolytic effect of pterostilbene
HUE034886T2 (hu) 2013-03-15 2018-03-28 Glia Llc Gyógyszerek cranialis adagolása
CN103333141B (zh) * 2013-06-05 2015-04-29 宁波大学 一种白藜芦醇低聚茋类化合物及其制备方法和应用
JP6406865B2 (ja) * 2014-04-25 2018-10-17 森永製菓株式会社 濃度測定方法
JP6463956B2 (ja) * 2014-11-28 2019-02-06 キユーピー株式会社 乳化組成物及びその製造方法
CN104706627A (zh) * 2015-03-12 2015-06-17 厦门大学 一种治疗缺血性脑中风的药物
WO2017011318A1 (en) 2015-07-10 2017-01-19 University Of Miami Methods for treating mucopolysaccharidosis
WO2018039207A1 (en) * 2016-08-22 2018-03-01 Elysium Health, Inc. Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders
US20200085849A1 (en) * 2017-05-18 2020-03-19 Elysium Health, Inc. Methods and compositions for improving sleep
JP6619108B2 (ja) * 2019-01-07 2019-12-11 キユーピー株式会社 乳化組成物及びその製造方法
CN111569084B (zh) * 2019-02-19 2021-07-13 中国科学院上海药物研究所 基于柳胺酚和紫檀芪的成环偶联分子dcz0801类化合物、其制备方法及用途
CN110075094A (zh) * 2019-02-27 2019-08-02 延边大学 紫檀芪在制备药物或保健品中的应用
CN112618520A (zh) * 2021-01-14 2021-04-09 姚大纯 紫檀芪或白藜芦醇在制备用于治疗或改善孤独症谱系障碍的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010095943A2 (en) * 2009-02-20 2010-08-26 N.V. Nutricia Use of resveratrol or another hydroxylated stilbene for preserving cognitive functioning

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060057231A1 (en) * 2004-08-19 2006-03-16 Rimando Agnes M Pterostilbene as a new agonist for the peroxisome proliferator-activated receptor alpha isoform
US20060216331A1 (en) * 2005-02-28 2006-09-28 Lines Thomas C Composition for treating mental health disorders
US20080108574A1 (en) * 2006-09-27 2008-05-08 Braincells, Inc. Melanocortin receptor mediated modulation of neurogenesis
US20090069444A1 (en) * 2007-09-07 2009-03-12 The United States Of America, As Represented By Th E Secretary Of Agriculture Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration
WO2009082459A2 (en) * 2007-12-24 2009-07-02 Natrol, Inc. Anti-aging composition containing resveratrol and method of administration
JP5526762B2 (ja) * 2009-02-17 2014-06-18 Ｊｎｃ株式会社 誘電率異方性が負の液晶性化合物、これを用いた液晶組成物および液晶表示素子
EP2445488B1 (en) * 2009-06-22 2020-03-18 Indus Biotech Private Limited Process for obtaining purified pterostilbene and methods of use thereof
EP2322159A1 (en) * 2009-10-30 2011-05-18 Green Molecular, S.L. Use of pterostilbene (pter) as medicament for prevention and/or treatment of skin diseases, damages or injures or as cosmetic
US9439875B2 (en) * 2011-05-11 2016-09-13 The United States Of America, As Represented By The Secretary Of Agriculture Anxiolytic effect of pterostilbene

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010095943A2 (en) * 2009-02-20 2010-08-26 N.V. Nutricia Use of resveratrol or another hydroxylated stilbene for preserving cognitive functioning

Also Published As

Publication number Publication date
BR112013028776B1 (pt) 2022-04-19
JP2017014284A (ja) 2017-01-19
AU2012253479A1 (en) 2013-11-28
EP2706992B1 (en) 2019-09-04
EP2706992A2 (en) 2014-03-19
JP6027607B2 (ja) 2016-11-16
HK1194302A1 (zh) 2014-10-17
WO2012154956A3 (en) 2013-01-24
KR20140107112A (ko) 2014-09-04
AU2012253479B2 (en) 2016-12-22
KR101929074B1 (ko) 2018-12-13
WO2012154956A2 (en) 2012-11-15
JP2014514361A (ja) 2014-06-19
US9439875B2 (en) 2016-09-13
BR112013028776A2 (pt) 2017-01-24
CA2839309C (en) 2019-05-07
CN103561729A (zh) 2014-02-05
US20160067192A1 (en) 2016-03-10
CA2839309A1 (en) 2012-11-15
EP2706992A4 (en) 2014-12-17

Similar Documents

Publication Publication Date Title
CN103561729B (zh) 紫檀茋在制造用于治疗、缓解或预防焦虑的药物组合物中的应用
RU2563991C2 (ru) Синергические комбинации каротиноидов и полифенолов
CA2903845C (en) Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
Fu et al. An integrated study on the comprehensive mechanism of Schisandra chinensis polysaccharides mitigating Alzheimer's disease in rats using a UPLC-Q-TOF-MS based serum and urine metabolomics strategy
CN115335068A (zh) 营养补充剂的组合物和方法
Yi et al. Marinoid J, a phenylglycoside from Avicennia marina fruit, ameliorates cognitive impairment in rat vascular dementia: A quantitative iTRAQ proteomic study
AU2018345749B2 (en) Methods for inhibiting conversion of choline to trimethylamine (TMA)
HK1194302B (en) Use of pterostilbene for the manufacture of a pharmaceutical composition for the treatment, alleviation, or prevention of anxiety
EP3522876B1 (en) Methods for inhibiting conversion of choline to trimethylamine (tma)
CN115006346B (zh) 精神疾病治疗剂的稳定化方法和包含阿米替林的组合物
Shafey et al. In silico and in vivo study: chamazulene and/or cinnamic acid modulate IRS2/GLUT4, HNF4α, GLUT2, redox system, DNA damage, and lipid profile signifying their potential antidiabetic effect
Hussein Coenzyme Q10 supplementation effect on systemic diseases
JP2025513458A (ja) ヨーグルト中の生体活性分子
KR20160101452A (ko) 레스베라트롤을 함유하는 ⅲ형 고셔병 치료용 약학 조성물
KR20150064728A (ko) 신체 내 사이클릭 아데노신 일인산의 함량 및 이용률을 증대시키기 위한 의약 조성물 및 그 제조 방법
US20130296441A1 (en) Anti-Obesity Properties of Pterostilbene
NZ711842B2 (en) Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1194302

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1194302

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160309

CF01 Termination of patent right due to non-payment of annual fee